539524 주식 개요 박사는 인도 및 국제적으로 병리학 조사를 수행하는 실험실을 운영하고 있습니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Dr. Lal PathLabs Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Dr. Lal PathLabs 과거 주가 현재 주가 ₹2,998.60 52주 최고치 ₹3,645.00 52주 최저치 ₹1,943.20 베타 0.34 1개월 변경 -0.18% 3개월 변경 사항 -12.16% 1년 변경 사항 13.45% 3년 변화 -21.76% 5년 변화 93.25% IPO 이후 변화 263.84%
최근 뉴스 및 업데이트
MD & Director recently sold ₹79m worth of stock Dec 12
MD & Director recently sold ₹35m worth of stock Nov 24
Company Secretary & Compliance Officer recently sold ₹1.7m worth of stock Nov 08
Upcoming dividend of ₹6.00 per share Oct 29
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Oct 24 Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025 더 많은 업데이트 보기
MD & Director recently sold ₹79m worth of stock Dec 12
MD & Director recently sold ₹35m worth of stock Nov 24
Company Secretary & Compliance Officer recently sold ₹1.7m worth of stock Nov 08
Upcoming dividend of ₹6.00 per share Oct 29
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Oct 24 Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025
Dr. Lal PathLabs Limited to Report Q2, 2025 Results on Oct 23, 2024 Oct 16
MD & Director recently sold ₹28m worth of stock Aug 20
Price target increased by 7.2% to ₹2,794 Aug 08
First quarter 2025 earnings: EPS exceeds analyst expectations Aug 08
Dr. Lal PathLabs Limited Approves Interim Dividend for the Fiscal Year 2024-25 Aug 07
Dr. Lal PathLabs Limited to Report Q1, 2025 Results on Aug 07, 2024 Jul 31
Non Executive Director recently sold ₹14m worth of stock Jul 02
MD & Director recently sold ₹20m worth of stock Jun 25
MD & Director recently sold ₹28m worth of stock Jun 13
MD & Director recently sold ₹37m worth of stock Jun 04
Upcoming dividend of ₹6.00 per share Jun 03
MD & Director recently sold ₹29m worth of stock May 29
MD & Director recently sold ₹36m worth of stock May 17 Dr. Lal PathLabs Limited, Annual General Meeting, Jun 29, 2024
Full year 2024 earnings: Revenues and EPS in line with analyst expectations May 11
Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024 May 11
Dr. Lal PathLabs Limited to Report Q4, 2024 Results on May 10, 2024 May 05
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024 Apr 28
MD & Director recently sold ₹33m worth of stock Mar 26
MD & Director recently sold ₹23m worth of stock Mar 09
MD & Director recently sold ₹43m worth of stock Feb 18
Upcoming dividend of ₹12.00 per share at 0.7% yield Feb 06
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Feb 02
Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24 Feb 01
Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024 Jan 25
Chief Executive Officer recently sold ₹7.6m worth of stock Dec 24
Chief Executive Officer recently sold ₹2.6m worth of stock Dec 16
Non Executive Director recently sold ₹7.8m worth of stock Nov 11
Price target increased by 8.0% to ₹2,353 Nov 07
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 03
Dr. Lal PathLabs Limited to Report Q2, 2024 Results on Nov 02, 2023 Oct 26
MD & Director recently sold ₹43m worth of stock Oct 01
Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023 Sep 13
Dr. Lal PathLabs Limited Announces Change in Directorate Aug 22
Dr. Lal PathLabs Limited Announces Change in Directorate Aug 21
MD & Director recently sold ₹32m worth of stock Aug 12
Upcoming dividend of ₹12.00 per share at 0.5% yield Aug 04
Price target increased by 7.2% to ₹2,091 Jul 29
Dr. Lal PathLabs Limited, Annual General Meeting, Sep 12, 2023 Jul 29
Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24 Jul 28
First quarter 2024 earnings released: EPS: ₹9.95 (vs ₹6.97 in 1Q 2023) Jul 28
MD & Director recently sold ₹41m worth of stock Jun 10
MD & Director recently sold ₹43m worth of stock May 19 Dr. Lal Pathlabs Limited Approves Appointment of Vinay Gujral as Company Secretary
Full year 2023 earnings: EPS and revenues miss analyst expectations May 12
MD & Director recently sold ₹14m worth of stock Mar 26
MD & Director recently sold ₹48m worth of stock Mar 02
MD & Director recently sold ₹41m worth of stock Feb 18
Rajat Kalra Resigns as Company Secretary and Compliance Officer of Dr. Lal Pathlabs Limited, Effective on or Before May 04, 2023 Feb 14
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Feb 05
Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire additional 10% stake in Aprl Pathlabs Private Limited for INR 7.5 million. Jan 31
Dr. Lal PathLabs Limited to Report Q3, 2023 Results on Feb 02, 2023 Jan 24
Chief Executive Officer recently sold ₹3.6m worth of stock Dec 27
MD & Director recently sold ₹48m worth of stock Dec 16
MD & Director recently sold ₹61m worth of stock Dec 04
MD & Director recently sold ₹57m worth of stock Nov 25
Insufficient new directors Nov 16
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 09
Dr. Lal PathLabs Limited to Report Q2, 2023 Results on Nov 08, 2022 Nov 02
MD & Director recently sold ₹33m worth of stock Sep 14
Non Executive Director recently sold ₹2.5m worth of stock Aug 24
MD & Director recently sold ₹117m worth of stock Aug 05
Dr. Lal Pathlabs Limited Declares an Interim Dividend for the Financial Year 2022-23, Payable on or Before August 26, 2022 Jul 29
First quarter 2023 earnings: EPS misses analyst expectations Jul 29
Dr. Lal PathLabs Limited to Report Q1, 2023 Results on Jul 28, 2022 Jul 21
Dr. Lal Pathlabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2022 Jul 01
Non-Executive Director recently sold ₹164m worth of stock Jun 24
Price target decreased to ₹2,536 Jun 18
Upcoming dividend of ₹6.00 per share Jun 15
Dr. Lal Pathlabs Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022 Jun 10
Investor sentiment improved over the past week Jun 01
Chief Executive Officer recently sold ₹4.0m worth of stock May 27
Consensus EPS estimates fall by 16% May 24
Price target decreased to ₹2,829 May 19
Dr. Lal Pathlabs Limited Proposes Final Dividend for the Year Ended March 31, 2022 May 18
Full year 2022 earnings: EPS and revenues miss analyst expectations May 18
Dr. Lal PathLabs Limited, Annual General Meeting, Jun 30, 2022 May 18
Dr. Lal PathLabs Limited to Report Q4, 2022 Results on May 17, 2022 May 07
Insufficient new directors Apr 27
Insufficient new directors Apr 01
Insider recently sold ₹1.4m worth of stock Mar 24
MD & Director recently sold ₹36m worth of stock Mar 13
Insufficient new directors Mar 02
MD & Director recently sold ₹37m worth of stock Feb 27
Insider recently sold ₹2.7m worth of stock Feb 20
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 13
Dr. Lal PathLabs Limited to Report Q3, 2022 Results on Feb 10, 2022 Feb 03
Investor sentiment deteriorated over the past week Jan 21
Chief Executive Officer recently sold ₹2.6m worth of stock Dec 25
Chief Operating Officer recently sold ₹6.9m worth of stock Dec 17
MD & Director recently sold ₹37m worth of stock Dec 02 주주 수익률 539524 IN Healthcare IN 마켓 7D 2.6% 1.1% -0.3% 1Y 13.5% 38.5% 16.3%
전체 주주 수익률 보기
수익률 대 산업: 539524 지난 1년 동안 38.5 %를 반환한 Indian Healthcare 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: 539524 지난 1년 동안 16.3 %를 반환한 Indian 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is 539524's price volatile compared to industry and market? 539524 volatility 539524 Average Weekly Movement 3.8% Healthcare Industry Average Movement 5.3% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.1%
안정적인 주가: 539524 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: 539524 의 주간 변동성 ( 4% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 박사는 인도 및 국제적으로 병리학 조사를 수행하는 실험실을 운영하고 있습니다. 이 회사는 생화학, 혈액학, 조직병리학, 미생물학, 전기영동, 면역화학, 면역학, 바이러스학, 세포학 및 기타 병리학 및 방사선 조사의 다양한 분야에 대한 병리학적 조사를 제공합니다. 또한 교육 프로그램도 제공합니다.
자세히 보기 Dr. Lal PathLabs Limited 기본 사항 요약 Dr. Lal PathLabs 의 수익과 매출은 시가총액과 어떻게 비교하나요? 539524 기본 통계 시가총액 ₹246.19b 수익(TTM ) ₹4.01b 수익(TTM ) ₹23.46b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 539524 손익 계산서(TTM ) 수익 ₹23.46b 수익 비용 ₹9.89b 총 이익 ₹13.57b 기타 비용 ₹9.56b 수익 ₹4.01b
주당 순이익(EPS) 48.18 총 마진 57.84% 순이익 마진 17.11% 부채/자본 비율 2.0%
539524 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기 기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/31 12:04 장 마감 주가 2024/12/31 00:00 수익 2024/09/30 연간 수익 2024/03/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Dr. Lal PathLabs Limited 44 애널리스트 중 22 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Prashant Nair Ambit Capital null null Antique Stockbroking Ltd. Harith Ahamed Avendus Spark
41 더 많은 분석가 보기 
